Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and autonomic neuropathy with intellectual disability
Sonja Neuser,Barbara Brechmann,Gali Heimer,Ines Brösse,Susanna Schubert,Lauren O'Grady,Michael Zech,Siddharth Srivastava,David A Sweetser,Yasemin Dincer,Volker Mall,Juliane Winkelmann,Christian Behrends,Basil T Darras,Robert J Graham,Parul Jayakar,Barry Byrne,Bat El Bar-Aluma,Yael Haberman,Amir Szeinberg,Hesham M Aldhalaan,Mais Hashem,Amal Al Tenaiji,Omar Ismayl,Asma E Al Nuaimi,Karima Maher,Shahnaz Ibrahim,Fatima Khan,Henry Houlden,Vijayalakshmi S Ramakumaran,Alistair T Pagnamenta,Jennifer E Posey,James R Lupski,Wen-Hann Tan,Gehad ElGhazali,Isabella Herman,Tatiana Muñoz,Gabriela M Repetto,Angelika Seitz,Mandy Krumbiegel,Maria Cecilia Poli,Usha Kini,Stephanie Efthymiou,Jens Meiler,Reza Maroofian,Fowzan S Alkuraya,Rami Abou Jamra,Bernt Popp,Bruria Ben-Zeev,Darius Ebrahimi-Fakhari
DOI: https://doi.org/10.1002/humu.24206
Abstract:Bi-allelic TECPR2 variants have been associated with a complex syndrome with features of both a neurodevelopmental and neurodegenerative disorder. Here, we provide a comprehensive clinical description and variant interpretation framework for this genetic locus. Through international collaboration, we identified 17 individuals from 15 families with bi-allelic TECPR2-variants. We systemically reviewed clinical and molecular data from this cohort and 11 cases previously reported. Phenotypes were standardized using Human Phenotype Ontology terms. A cross-sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal hypopnea as core manifestations. A review of brain magnetic resonance imaging scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct variants. Missense variants in TECPR2 are predominantly located in the N- and C-terminal regions containing β-propeller repeats. Despite constituting nearly half of disease-associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains challenging. We estimate a pathogenic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/treatment of individuals with TECPR2-associated disorder. This sets the stage for future prospective natural history studies.